Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia:. A PET study with [11C]verapamil as a probe for P-glycoprotein function

Psychiatry Research - Neuroimaging

Volumn 183, Issue 2, 2010, Pages 151-156

  de Klerk, Onno L ^a,b   Willemsen, Antoon T M ^a   Bosker, Fokko J ^a   Bartels, Anna L ^a   Hendrikse, N Harry ^c   den Boer, Johan A ^a   Dierckx, Rudy A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Psychiatric Hospital GGZ Drenthe   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Blood brain barrier; P glycoprotein; Positron emission tomography; Schizophrenia; 11C verapamil

Indexed keywords

GLYCOPROTEIN P; NEUROLEPTIC AGENT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VERAPAMIL C 11;

ADULT; AGED; AMYGDALOID NUCLEUS; ARTICLE; BASAL GANGLION; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMAN; MALE; POLYMERASE CHAIN REACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TEMPORAL CORTEX;

EID: 77955050305     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2010.05.002     Document Type: Article

References (61)

1. Abrahim A., Luurtsema G., Bauer M., Karch R., Lubberink M., Pataraia E., Joukhadar C., Kletter K., Lammertsma A.A., Baumgartner C., Muller M., Langer O. Peripheral metabolism of (R)-[(11)C]verapamil in epilepsy patients. European Journal of Nuclear Medicine and Molecular Imaging 2008, 35:116-123.
2. Alenius M., Wadelius M., Dahl M.L., Hartvig P., Lindström L., Hammarlund-Udenaes M. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. Journal of Psychiatric Research 2008, 42:884-893.
3. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual Review of Pharmacology and Toxicology 1999, 39:361-398.
4. Arolt V., Rothermundt M., Wandinger K.P., Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Molecular Psychiatry 2000, 5:150-158.
5. Bartels A.L., Willemsen A.T., Kortekaas R., de Jong B.M., de Vries R., de Klerk O., van Oostrom J.C., Portman A., Leenders K.L. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. Journal of Neural Transmission 2008, 115:1001-1009.
6. Bauer B., Hartz A.M., Fricker G., Miller D.S. Modulation of p-glycoprotein transport function at the blood-brain barrier. Experimental Biology and Medicine (Maywood.) 2005, 230:118-127.
7. Bauer B., Hartz A.M., Miller D.S. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Molecular Pharmacology 2007, 71:667-675.
8. Di N.F., Mercer S.J., Knight L.A., Gabriel F.G., Whitehouse A., Sharma S., Fernando A., Glaysher S., Di S., Johnson P., Somers S.S., Toh S., Higgins B., Lamont A., Gulliford T., Hurren J., Yiangou C., Cree I.A. Cancer cell adaptation to chemotherapy. BMC Cancer 2005, 5:78.
9. Drzyzga L., Obuchowicz E., Marcinowska A., Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain, Behavior, and Immunity 2006, 20:532-545.
10. Eichelbaum M., Fromm M.F., Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Therapeutic Drug Monitoring 2004, 26:180-185.
11. Eisel U.L. Cytokines in degenerative brain diseases: lessons from transgenic animals. Current Topics in Microbiology and Immunology 2002, 265:49-62.
12. El Ela A.A., Hartter S., Schmitt U., Hiemke C., Spahn-Langguth H., Langguth P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds-implications for pharmacokinetics of selected substrates. The Journal of Pharmacy and Pharmacology 2004, 56:967-975.
13. Elsinga H., Hendrikse N.H., Bart J., Vaalburg W., van Waarde A. PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Current Pharmaceutical Design 2004, 10:1493-1503.
14. Fernandez C., Buyse M., German-Fattal M., Gimenez F. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. Journal of Pharmacy & Pharmaceutical Sciences 2004, 7:359-371.
15. Fontaine V., Mohand-Said S., Hanoteau N., Fuchs C., Pfizenmaier K., Eisel U. Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. Journal of Neuroscience 2002, 22:RC216.
16. Gilmore J.H., Jarskog L.F., Vadlamudi S., Lauder J.M. Prenatal infection and risk for schizophrenia: IL-Iß, IL-6 and TNF? inhibit cortical neuron dendrite development. Neuropsychopharmacology 2004, 29:1221-1229.
17. Hanson D.R., Gottesman I.I. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Medical Genetics 2005, 6:7.
18. Harrison B.J., Yucel M., Shaw M., Brewer W.J., Nathan J., Strother S.C., Olver J.S., Egan G.F., Velakoulis D., McGorry D., Pantelis C. Dysfunction of dorsolateral prefrontal cortex in antipsychotic-naive schizophreniform psychosis. Psychiatry Research 2006, 148:23-31.
19. Hartz A.M., Bauer B., Fricker G., Miller D.S. Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Molecular Pharmacology 2006, 69:462-470.
20. Hendrikse N.H., de Vries E.G., Eriks-Fluks L., van der Graaf W.T., Hospers G.A., Willemsen A.T., Vaalburg W., Franssen E.J. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Research 1999, 59:2411-2416.
21. Honea R., Crow T.J., Passingham D., Mackay C.E. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. The American Journal of Psychiatry 2005, 162:2233-2245.
22. Ichise M., Toyama H., Innis R.B., Carson R.E. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. Journal of Cerebral Blood Flow and Metabolism 2002, 22:1271-1281.
23. Johnson W.W. P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: modulation of chemotherapy resistance. Methods & Findings in Experimental & Clinical Pharmacology 2002, 24:501-514.
24. Kastelic, M., Koprivsek, J., Plesnicar, B.K., Serretti, A., Mandelli, L., Locatelli, I., Grabnar, I., Dolzan, V., 2010. MDR1 gene polymorphisms and response to acute risperidone treatment. Progress in Neuropsychopharmacology and Biological Psychiatry 34 (2), 387--392.
25. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
26. Kirschbaum K.M., Henken S., Hiemke C., Schmitt U. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behavioural Brain Research 2008, 188:298-303.
27. Kortekaas R., Leenders K.L., van Oostrom J.C., Vaalburg W., Bart J., Willemsen A.T., Hendrikse N.H. Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo. Annals of Neurology 2005, 57:176-179.
28. Kuzman M.R., Medved V., Bozina N., Hotujac L., Sain I., Bilusic H. The influence of 5-HT2C and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Research 2008, 160:308-315.
29. Lin Y.C., Ellingrod L., Bishop J.R., Miller D.S. The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Therapeutic Drug Monitoring 2006, 28:668-672.
30. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nuclear Medicine and Biology 2000, 27:661-670.
31. Lown K.S., Mayo R.R., Leichtman A.B., Hsiao H.L., Turgeon D.K., Schmiedlin-Ren P., Brown M.B., Guo W., Rossi S.J., Benet L.Z., Watkins B. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clinical Pharmacology & Therapeutics 1997, 62:248-260.
32. Lubberink M., Luurtsema G., van Berckel B.N., Boellaard R., Toornvliet R., Windhorst A.D., Franssen E.J., Lammertsma A.A. Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. Journal of Cerebral Blood Flow and Metabolism 2007, 27:424-433.
33. Matheny C.J., Lamb M.W., Brouwer K.R., Pollack G.M. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001, 21:778-796.
34. Müller N., Riedel M., Hadjamu M., Schwarz M.J., Ackenheil M., Gruber R. Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. The American Journal of Psychiatry 1999, 156:634-636.
35. Pantelis C., Yucel M., Wood S.J., Velakoulis D., Sun D., Berger G., Stuart G.W., Yung A., Phillips L., McGorry D. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophrenia Bulletin 2005, 31:672-696.
36. Pauli-Magnus C., von Richter O., Burk O., Ziegler A., Mettang T., Eichelbaum M., Fromm M.F. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. The Journal of Pharmacology and Experimental Therapeutics 2000, 293:376-382.
37. Pechandova K., Buzkova H., Slanar O., Perlik F. Polymorphisms of the MDR1 gene in the Czech population. Folia Biologica (Praha) 2006, 52:184-189.
38. Roberts D.J., Goralski K.B. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opinion on Drug Metabolism & Toxicologyl 2008, 4:1245-1264.
39. Rothermundt M., Arolt V., Bayer T.A. Review of immunological and immunopathological findings in schizophrenia. Brain, Behavior, and Immunity 2001, 15:319-339.
40. Sakaeda T., Nakamura T., Okumura K. Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Current Topics in Medicinal Chemistry 2004, 4:1385-1398.
41. Sasongko L., Lin J.M., Muzi M., Mankoff D.A., Yang X., Collier A.C., Shoner S.C., Unadkat J.D. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clinical Pharmacology & Therapeutics 2005, 77:503-514.
42. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77:491-502.
43. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. The Journal of Clinical Investigation 1996, 97:2517-2524.
44. Selemon L.D. Regionally diverse cortical pathology in schizophrenia: clues to the etiology of the disease. Schizophrenia Bulletin 2001, 27:349-377.
45. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59(Suppl 20):22-33.
46. Shinkai T., De, L., V, Utsunomiya K., Sakata S., Inoue Y., Fukunaka Y., Hwang R., Ohmori O., Kennedy J.L., Nakamura J. Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia-hyponatremia in schizophrenia. Neuromolecular Medicine 2008, 10:362-367.
47. Stolp H.B., Dziegielewska K.M. Review: Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathology and Applied Neurobiology 2009, 35:132-146.
48. Tan K.H., Purcell W.M., Heales S.J., McLeod J.D., Hurst R.D. Evaluation of the role of P-glycoprotein in inflammation induced blood-brain barrier damage. NeuroReport 2002, 13:2593-2597.
49. Tan E.K., Drozdzik M., Bialecka M., Honczarenko K., Klodowska-Duda G., Teo Y.Y., Tang K., Wong L.P., Chong S.S., Tan C., Yew K., Zhao Y., Lee C.G. Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neuroscience Letters 2004, 372:240-244.
50. Uhr M., Grauer M.T., Yassouridis A., Ebinger M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. Journal of Psychiatric Research 2007, 41:179-188.
51. Wang J.S., Ruan Y., Taylor R.M., Donovan J.L., Markowitz J.S., DeVane C.L. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. The International Journal of Neuropsychopharmacology 2004, 7:415-419.
52. Wang J.S., Zhu H.J., Markowitz J.S., Donovan J.L., DeVane C.L. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 2006, 187:415-423.
53. Wang J.S., Zhu H.J., Markowitz J.S., Donovan J.L., DeVane C.L. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 2006, 187:415-423.
54. Weber C.C., Kressmann S., Ott M., Fricker G., Muller W.E. Inhibition of P-glycoprotein function by several antidepressants may not contribute to clinical efficacy. Pharmacopsychiatry 2005, 38:293-300.
55. Wegman T.D., Maas B., Elsinga H., Vaalburg W. An improved method for the preparation of [11C]verapamil. Applied Radiation and Isotopes 2002, 57:505-507.
56. Woodahl E.L., Ho R.J. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Current Drug Metabolism 2004, 5:11-19.
57. Xing Q., Gao R., Li H., Feng G., Xu M., Duan S., Meng J., Zhang A., Qin S., He L. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006, 7:987-993.
58. Yasui-Furukori N., Mihara K., Takahata T., Suzuki A., Nakagami T., De R., Tateishi T., Kondo T., Kaneko S. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Britisch Journal of Clinical Pharmacology 2004, 57:569-575.
59. Yasui-Furukori N., Saito M., Nakagami T., Kaneda A., Tateishi T., Kaneko S. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Progress in Neuropsychopharmacology & Biological Psychiatry 2006, 30:286-291.
60. Yasui-Furukori N., Tsuchimine S., Saito M., Nakagami T., Sato Y., Kaneko S. Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Progress in Neuropsychopharmacology & Biological Psychiatry 2007, 31:1230-1234.
61. Zhu H.J., Wang J.S., Markowitz J.S., Donovan J.L., Gibson B.B., DeVane C.L. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology 2007, 32:757-764.